Heterogeneity of breast cancer I stage: clinical and prognostic value of the carcinoma size T1A, T1B and T1C

Irina V. Kolyadina; I. V Poddubnaya; O. P Trofimova; G. A Frank; D. V Komov; A. I Karseladze; A. S Ozhereliev

doi:10.17816/onco40107

Russian Journal of Oncology ›› 2015, Vol. 20 ›› Issue (1) : 17 -22. DOI: 10.17816/onco40107

Articles

research-article

Heterogeneity of breast cancer I stage: clinical and prognostic value of the carcinoma size T1A, T1B and T1C

Author information +

History +

PDF

Abstract

During last 25 years there has been a progressive increase in the share of «small» tumors (T1a and T1b) in breast cancer stage I. Biological characteristics of tumor size T1a, T1b and T1c are different. Tumors less then 5mm have favorable biology: a high rate of luminal A subtype of breast cancer that affects the minimum proportion of relapses of the breast cancer and high rates of long-term survival. Biological characteristics of tumor with T1b and T1c size are more aggressive and presented by a high frequency of ductal carcinoma with luminal B and triple-negative immunophenotype, which significantly decreases the prognosis of the disease. Biology «small» tumors should be considered for choosing the optimal adjuvant treatment algorithm for breast cancer stage I.

Keywords

breast cancer stages I / tumor size T1a-b-c / biological subtypes of breast cancer / relapses-free survival / cancer-specific survival

Cite this article

Download citation ▾

Irina V. Kolyadina, I. V Poddubnaya, O. P Trofimova, G. A Frank, D. V Komov, A. I Karseladze, A. S Ozhereliev. Heterogeneity of breast cancer I stage: clinical and prognostic value of the carcinoma size T1A, T1B and T1C. Russian Journal of Oncology, 2015, 20(1): 17-22 DOI:10.17816/onco40107

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	GLOBOGAN 2012; www.http://globocan.iarc.fr

[2]	Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Состояние онкологической помощи населению России в 2013 году. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России; 2014. www.

[3]	Аксель Е.М. Заболеваемость и смертность от рака молочной железы в России. В кн.: Материалы большой конференции RUSSCO «Рак молочной железы» 22-24 января 2014 г. М.; 2014: 35-8.

[4]	Livi L., Meattini I., Saieva C. et al. Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer. Cancer2012; 118 (13): 3236-43.

[5]	Gonzalez-Angulo A.M., Litton J.K., Broglio K.R. et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J. Clin. Oncol. 2009; 27 (34): 5700-6.

[6]	Schroeder M.C., Lynch C.F., Abu-Hejleh T. et al. Chemotherapy use and surgical treatment by receptor subtype in node-negative T1a and T1b female breast cancers, Iowa SEER Registry, 2010-2012. Clin. Breast Cancer. 2014 Aug 18. pii: S1526-8209(14)00164-5.

[7]	Harbeck N., Thomssen Ch., Gnant M. Brief Preliminary Summary of the Consensus Discussion. Breast Care (Basel). 2013; 8 (2): 102-9.

[8]	NCCN breast cancer guidelines professionals http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#breast

[9]	Schroeder M.C., Lynch C.F., Abu-Hejleh T., Chrischilles E. A., Thomas A. Chemotherapy use and surgical treatment by receptor subtype in node-negative T1a and T1b female breast cancers, Iowa SEER Registry, 2010-2012. Clin. Breast Cancer. 2014; 18. pii: S1526-8209 (14): 164-5.

[10]	Langagergaard V, Garne J.P., Vejborg I., Schwartz W., Bak M., Lernevall A. et al. Existing data sources for clinical epidemiology: the Danish Quality Database of Mammography Screening. Clin Epidemiol. 2013; 5: 81-8.